Praxis Precision Medicines, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Marcio Souza (CEO) and Timothy Kelly (CFO) issued standard Sarbanes-Oxley certifications on August 6, 2026 for Praxis Precision Medicines' Q2 2026 10-Q filing. Both officers certified that financial statements fairly present the company's condition and results of operations, disclosure controls are effective, and no material weaknesses or fraud involving management were identified. No specific financial data, transactions, or operational changes are disclosed in these certification exhibits alone.
Why this rating
These are boilerplate SOX 302/906 certifications—routine quarterly filing requirements. No material events, transactions, control failures, or restatements are mentioned. Standard administrative disclosure.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.